The importance of dc-mediated immune responses against tgfβ-producing tumours can be shown by systemic inhibition of tgfβ-mediated signalling using a tgfβ neutralizing antibody in combination with a dc vaccine or dcs in which tgfβ signalling is impaired by the expression of a dominant negative tgfβ type ii receptor (dntgfβrii) transgene 15,19 (unpubl. Here, TGFB1 is linked to neoplasm.